KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.19
−1.50%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$11.31
From 52W high−48.76%
Volume272631.00
Market cap$221.87M
P/E (TTM)—
P/S (TTM)14.8x
Div yield—
Key dataSep 18, 2026
Open
$11.31
From 52W high
−48.76%
Volume
272631.00
Market cap
$221.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
52.3
MomentumView details →
1D Return
−1.50%
YTD Return
−45.09%
SummaryUpdated Jun 1, 2026
Keros Therapeutics, Inc. (NASDAQ:KROS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Lexington, Massachusetts. The company went public in April 2020 and focuses on developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. Keros operates in the specialized field of protein therapeutics and small molecule drugs, targeting conditions affecting blood cell production and bone health.
Similar companies
Latest newsMore news →
Keros Therapeutics' board approved a $5 million share repurchase program of its common stock, following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals under the elritercept license agreement.12d agoDimensional Fund Advisors LP increased its stake in Keros Therapeutics, Inc. by 453.9% during the quarter, acquiring an additional 263,347 shares, as disclosed in a Form 13F filing.38d agoKeros Therapeutics will receive a $20 million development milestone payment from Takeda after the first patient was dosed in the ELRiSE MDS clinical trial.52d ago